NeuroSense Therapeutics Ltd

NASDAQ:NRSN  
1.79
+0.05 (+2.87%)
Products, Regulatory

NeuroSense Announces Positive PrimeC Toxicology Data Supportive Of Current Phase IIb PARADIGM ALS Clinical Trial

Published: 09/20/2022 13:42 GMT
NeuroSense Therapeutics Ltd (NRSN) - Neurosense Announces Positive Primec Toxicology Data Supportive of Current Phase Iib Paradigm Als Clinical Trial.
Neurosense Therapeutics Ltd - Primec is Safe and Tolerable at Over 4x Maximal Clinical Dose.
Neurosense Therapeutics Ltd - Data Support Current Phase Iib Paradigm Study Design, New Primec Formulation, and Potential Favorable Clinical Trial Outcome.